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Abstract
Background: Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in
the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have
on the use of opioids in adolescents for the management of pain disorders in the ED.
Methods: This was a cross-sectional study using data from the National Hospital Ambulatory Medical Care Survey
from 2006 to 2016. Multivariate models were used to evaluate the role of race/ethnicity in the receipt of opioid
agonists while in the ED. All ED visits with patients aged 11–21 years old were analyzed. Races/ethnicities were
stratified as non-Hispanic Whites, non-Hispanic Blacks, and Hispanics. In addition to race, statistical analysis included
the following covariates: pain score, pain diagnosis, age, region, sex, and payment method.
Results: There was a weighted total of 189,256,419 ED visits. Those visits involved 109,826,315 (58%) non-Hispanic
Whites, 46,314,977 (24%) non-Hispanic Blacks, and 33,115,127 (18%) Hispanics, with 21.6% (95% CI, 21.1%-22.1),
15.2% (95% CI, 14.6–15.9%), and 17.4% (95% CI, 16.5–18.2%) of those visits reporting use of opioids, respectively.
Regardless of age, sex, and region, non-Hispanic Whites received opioids at a higher rate than non-Hispanic Blacks
and Hispanics. Based on diagnosis, non-Hispanic Whites received opioids at a higher rate in multiple pain
diagnoses. Additionally, non-Hispanic Blacks and Hispanics were less likely to receive an opioid when reporting
moderate pain (aOR = 0.738, 95% CI 0.601–0.906, aOR = 0.739, 95% CI 0.578–0.945, respectively) and severe pain
(aOR = 0.580, 95% CI 0.500–0.672, aOR = 0.807, 95% CI 0.685–0.951, respectively) compared to non-Hispanic Whites.
Conclusions: Differences in the receipt of opioid agonists in EDs among the races/ethnicities exist, with more non-
Hispanic Whites receiving opioids than their minority counterparts. Non-Hispanic Black women may be an
especially marginalized population. Further investigation into sex-based and regional differences are needed.
Keywords: Pediatrics, Adolescents, Emergency department, Ethnology, Analgesics, Pain, National, Young adult,
Minority, Race
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Background
Racial and ethnic inequities occur in a variety of aspects
of our healthcare system in both adults and pediatrics
[1]. In the emergency department (ED), Non-Hispanic
Blacks and Hispanics wait significantly longer to receive
care [2–4], have lower hospital admission rates [5], re-
ceive less diagnostic testing to evaluate chest pain [6],
and receive fewer opioids to treat pain than Non-
Hospanic Whites [7–9]. Although other studies have not
found significant differences in pain management based
on race and ethnicity [10–13], these studies have
assessed all pain medications and not specifically the re-
ceipt of an opioid agonist. Additionally, studies have
demonstrated that racial minorities, particularly non-
Hispanic Blacks, report more pain than non-Hispanic
Whites, while simultaneously receiving fewer opioid ago-
nists during those visits [14, 15]. Disparities in pain
management may have an adverse effect on minoritiy
groups by creating significant barriers to obtaining qual-
ity health care, diminishing quality of life, and increasing
societal costs.
Compared to the adult population, there is limited re-
search in pain management disparaties among pediatrics,
particularly in assessing the receipt of opioids in EDs.
The use of opioids to treat pediatrics with moderate to
severe pain is especially beneficial in moderate to severe
pain that does not respond to acetaminophen and non-
steroidal anti-inflammatory drugs [16, 17]. Yet, opioid
use has come under increased scrutiny in this popula-
tion, resulting in decreased use in pediatrics within the
ED. [3, 18]
Further complicating the discussion surrounding the
use of opioids in pediatric patients is the reporting that
opioid-related deaths among pediatrics aged 0–19 years
have increased in recent history [19]. Within pediatrics,
adolescents have been shown to be prescribed more opi-
oids than pre-adolescent patients [3]. The use of opioids
is especially concerning in adolescent patients as a
whole, as recent studies suggest the prevalence of opioid
misuse is high within this age group; however, previous
studies have not suggested that Non-Hispanic Blacks or
Hispanics have higher rates of opioid misuse [20–22]. In
addition, research has suggested that opioid exposure in
adolescence significantly increases the risk of subsequent
opioid misuse or abuse later in life, which is also likely
to encourage further restrictions on the use of opioids in
this patient population [23, 24]. Although the risks asso-
ciated with such potential for misuse is concerning,
there are growing concerns over whether these concerns
are resulting in the expansion of opioid prescribing dis-
parities for Non-Hispanic Blacks and Hispanics, com-
pared to their Non-Hispanic White counterparts [25].
Prescribers must find a balance between the conflicting
risk of potential undertreatment and the potential
adverse consequences of opioid use and ensure prescrib-
ing decisions are disconnected from any potential racial/
ethnic bias. Managing pain must be driven by patient
needs, based on clinical evaluation, without influence
from patient specific demographic factors such as race/
ethnicity.
Previous work conducted by Tomaszewski and col-
leagues found that Non-Hispanic White pediatric pa-
tients had received opioid agonists in EDs at a higher
rate than Non-White pediatric patients in EDs, in
addition to other non-clinically-driven prescribing pat-
terns [3]. The existence of racial/ethnic inequalities in
receipt of opioid agonists in EDs suggests the need to
conduct a deeper examination of racial/ethnic dispar-
ities and whether they can be explained by other fac-
tors including geographic region, payment method,
pain diagnosis, age, sex, episode of care, metropolitan
setting, or time period. To date, no research has eval-
uated the impact of potential confounding clinical
(pain score and pain diagnosis) and non-clinical fac-
tors (region of care, sex, age, and payment method)
on pediatric opioid prescribing. Understanding the
presence and degree of the racial/ethnic differences in
the context of these factors provides insight on na-
tional opioid prescribing patterns regarding inequal-
ities of healthcare. This study aims to further evaluate
how these factors are associated with racial/ethnic dif-
ferences in the receipt of opioid agonists among ado-
lescents in EDs and their trends over time.
Methods
Study design and setting
This study analyzed data collected from the Center
for Disease Control (CDC) and Prevention’s 2006–
2016 National Hospital Ambulatory Medical Care
Survey (NHAMCS). NHAMCS is conducted nationally
among all 50 states and the District of Colombia
using a representative sample of visits to hospital-
based outpatient clinics, emergency departments, and
ambulatory surgery locations in non-institutional and
short-stay hospitals. The survey employs a complex
four-stage study design. A detailed description of the
data collection methodology can be accessed at the
CDC’s National Center for Health Statistics (NCHS)
website [26, 27].
Population
Emergency department visits involving patients aged
11–21 years were included in the study and the study
population was stratified into age groups of 11–14, 15–
17, and 18–21 years old. This stratification was based on
the American Academy of Pediatrics’ definitions of early,
middle, and late adolescence [28].
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Outcome
The primary outcome was receipt of an opioid agonist
in the ED. Drugs are coded in terms of generic compo-
nent and therapeutic classification using Lexicon Plus®, a
comprehensive database of medications available in the
U.S. market. The usage of opioids was determined using
the CDC’s New Ambulatory Care Drug Database system,
with drugs being classified as opioid or other [29].
Independent variables
NHAMCS categorized ethnicity as Hispanic and non-
Hispanic. Race was categorized by White, Black, Ameri-
can Indian/Alaska Native, Asian, Native Hawaiian/Other
Pacific Islander, or Multiple Races. Accordingly, we con-
structed 3 cohorts: non-Hispanic white, non-Hispanic
Black, and Hispanic (Hispanic White and Hispanic
Black). All other races were not included in our analysis
since the resulting cohort sizes were lower than the
CDC’s recommended number of visits per cohort. To
examine the disparities of care for minorities, we used
non-Hispanic White patients as the control group.
When recording race/ethnicity, hospital staff were
instructed by NHAMCS to not ask the patient to self-
identify their race/ethnicity, unless it was hospital pro-
cedure to do so. Therefore, it is likely race/ethnicity
assigned to each patient reflects a clinician’s perception
of the patient’s race/ethnicity, and not necessarily what
classification the patient identifies with the most. Patient
age, sex, payment method (private, Medicaid, self-pay,
other payment method) were recorded at each visit. In-
formation on whether the episode was an initial visit or
follow-up visit was also collected. Healthcare institution
information was also collected to determine region
(Midwest, Northeast, South, West), and whether it was
in a metropolitan setting or not.
The NHAMCS uses a standard reason for visit classifi-
cation to code complaints, symptoms, or other reasons
for visit. The summary of codes and diagnoses can be
found in the NHAMCS micro-data file documentation
[30]. Reported pain diagnosis were maintained as indi-
vidual variables except for muscoloskeletal pain, which
included arthritis/joint pain, pelvic pain, back pain, and
neck pain. Pain was coded on a 1–4 scale, where a score
of 1 meant no pain, 2 indicated mild pain, 3 reflected
moderate pain, and 4 signaled severe pain [30]. A score
of 0 in NHAMCS meant no pain score was recorded.
Statistical analysis
All analyses were conducted on weighted data, as rec-
ommended by the CDC’s NCHS website. The weighting
is calculated using the most recent census data to pro-
vide a stratified representation of the national patient
population. All participants’ records were stored in a re-
lational database using the open-source database
software MySQL (v. 5.7.11, Oracle, Redwood Shores,
California). All analytics were performed using the open-
source statistical computing software R (v 3.2.3, R Foun-
dation, Vienna, Austria). The function svydesign from
the R package survey was used to account for stratified,
clustered, and weighted variables in the NHAMCS data.
Wald tests of association were used to determine signifi-
cance for bivariate analyses. Stepwise regression via
backward elimination was used including all independ-
ent variables mentioned above. Separate independent lo-
gistic regression models were run holding pain score
constant with race/ethnicity as the sole independent
variable and receipt of opioid as the dependent variable.
CDC detailed documentation of the NHAMCS instru-
ment, methodology and data files that were used as the
basis for these analyses are available elsewhere [31].
Results
Patient characteristics and overall trend
From 2006 through 2016 there was a weighted total of
189,256,419 ED visits involving patients aged 11–21
years at the time of visit with a reported race/ethnicity
of non-Hispanic Black, non-Hispanic White, or His-
panic. Those visits involved 46,314,977 (24%) non-
Hispanic Black, 33,115,127 (18%) Hispanic, and 109,826,
315 (58%) non-Hispanic White patients, with 15.2%
(95% CI, 14.6–15.9%), 17.4% (95% CI, 16.5–18.2%), and
21.6% (95% CI, 21.1–22.1%) of those visits associated
with receipt of an opioid, respectively (Table 1). Receipt
of an opioid across all races/ethnicities was greater dur-
ing the 2006–2011 timeframe compared to 2012–2016
(Table 1). In both time periods, non-Hispanic Whites re-
ceived an opioid more frequently than non-Hispanic
Blacks. However, compared to Hispanics, higher rates of
opioid receipt was reported in non-Hispanic Whites in
the 2006–2011 timeframe, but not 2012–2016.
Demographic factors
Across all age stratifications, non-Hispanic Whites were
prescribed more opioids than minority patients (Table 1).
Hispanics also tended to be prescribed more opioids
than non-Hispanic Blacks, with statistical significance
seen in the early- and late-adolescent ages. The largest
gap observed was between early-adolescent non-
Hispanic Blacks and non-Hispanic Whites, where opioid
receipt was reported in 8.4% (95% CI, 7.3–9.5%) and
14.2% (95% CI, 13.4–15.1%) of visits, respectively.
Comparing racial/ethnic ED opioid receipt based on
sex resulted in non-Hispanic White males and females
having greater rates of opioid receipt reported than their
Hispanic and non-Hispanic Black counterparts (Fig. 1).
Visits with non-Hispanic White males and females re-
ported opioid receipt in 21.9% (95% CI, 21.1–22.7%) and
21.4% (95% CI, 20.7–22.1%) of visits, respectively;
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Table 1 US emergency department visits for pediatric patients (2006–2016)a





opioids (weighted CI 95)b
Significance
All Visits non-Hispanic Black 46,314,977 7,060,196 15.2% (14.6–15.9%) TRUE
Hispanic 33,115,127 5,744,969 17.4% (16.5–18.2%) TRUE
non-Hispanic White 109,826,315 23,740,585 21.6% (21.1–22.1%) –
Age
11–14 non-Hispanic Black 10,357,118 871,910 8.4% (7.3–9.5%) TRUE
Hispanic 9,835,028 1,065,055 10.8% (9.5–12.1%) TRUE
non-Hispanic White 27,210,118 3,875,138 14.2% (13.4–15.1%) –
15–17 non-Hispanic Black 11,530,230 1,483,259 12.9% (11.6–14.1%) TRUE
Hispanic 8,476,686 1,267,072 15.0% (13.4–16.5%) TRUE
non-Hispanic White 28,845,980 5,411,450 18.8% (17.8–19.7%) –
18–21 non-Hispanic Black 24,427,629 4,705,027 19.3% (18.2–20.3%) TRUE
Hispanic 14,803,413 3,412,842 23.1% (21.7–24.5%) TRUE
non-Hispanic White 53,770,217 14,453,997 26.9% (26.1–27.7%) –
Metropolitan Setting
Metropolitan Area non-Hispanic Black 38,071,587 5,810,872 15.3% (14.5–16.0%) TRUE
Hispanic 27,392,274 4,773,270 17.4% (16.5–18.3%) TRUE
non-Hispanic White 76,616,787 17,818,822 23.3% (22.6–23.9%) –
Non-Metropolitan Area non-Hispanic Black 4,425,515 694,287 15.7% (12.8–18.5%) FALSE
Hispanic 2,084,413 340,727 16.4% (12.4–20.3%) FALSE
non-Hispanic White 23,766,791 4,322,886 18.2% (17.1–19.3%) –
Unknown/Missing Data non-Hispanic Black 3,817,875 555,037 14.5% (12.2–16.9%) FALSE
Hispanic 3,638,440 630,972 17.3% (14.8–19.9%) FALSE
non-Hispanic White 9,442,737 1,598,877 16.9% (15.3–18.5%) –
Episode Of Care
Initial visit to this ED non-Hispanic Black 36,540,026 5,541,337 15.2% (14.4–15.9%) TRUE
Hispanic 26,760,576 4,560,584 17.0% (16.1–18.0%) TRUE
non-Hispanic White 87,184,961 18,229,727 20.9% (20.3–21.5%)
Follow-up visit to this ED non-Hispanic Black 2,100,319 406,880 19.4% (16.0–22.7%) TRUE
Hispanic 1,535,101 304,995 19.9% (16.0–23.7%) TRUE
non-Hispanic White 4,612,751 1,227,153 26.6% (24.0–29.2%) –
Unknown/Missing Data non-Hispanic Black 7,674,632 1,111,979 14.5% (13.0–16.0%) TRUE
Hispanic 4,819,450 879,390 18.3% (16.3–20.2%) TRUE
non-Hispanic White 18,028,603 4,283,705 23.8% (22.5–25.0%) –
Year of Visit
2006–2011 non-Hispanic Black 26,272,954 4,547,058 17.3% (16.4–18.2%) TRUE
Hispanic 16,352,926 3,198,892 19.6% (18.4–20.7%) TRUE
non-Hispanic White 61,622,253 15,602,711 25.3% (24.6–26.0%) –
2012–2016 non-Hispanic Black 20,042,023 2,513,138 12.5% (11.5–13.6%) TRUE
Hispanic 16,762,201 2,546,077 15.2% (13.9–16.5%) FALSE
non-Hispanic White 48,204,062 8,137,874 16.9% (16.1–17.7%) –
aAll analyses accounts for the complex sampling design of NHAMCS
bTests are run at 95% Confidence intervals (P < 0.05)
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whereas visits with non-Hispanic Black males and fe-
males reported receipt of an opioid in 17.3% (95% CI,
16.2–18.4%) and 13.91% (95% CI,13.1–14.8%) of visits,
respectively. Visits with Hispanic males and females re-
ported opioid receipt in 17.5% (95% CI, 16.2–18.7%) and
17.3% (95% CI, 16.1–18.0%) of visits, respectively.
Based on regions, non-Hispanic Whites were signifi-
cantly prescribed more opioids than minorities in all re-
gions, with the exception of the West. There, non-
Hispanic Whites were prescribed more opioids than
non-Hispanic Blacks, but not Hispanics (Fig. 1). The lar-
gest disparity was observed in the Northeast, where
15.7% (95% CI, 14.8–16.7%) of non-Hispanic Whites,
9.2% (95% CI, 8.0–10.4%) of non-Hispanic Blacks, and
7.2% (95% CI, 6.1–8.3%) of Hispanics had reported re-
ceipt of an opioid within the ED. The Midwest and
South reported a similar pattern. Overall opioid use
within the ED appears to be highest in the West and
lowest in the Northeast (Fig. 1). An evaluation of opioid
use based on whether the hospital was located within a
metropolitan or non-metropolitan area are found in
Table 1.
Race/ethnicity differences were also observed in pay-
ment method, where ED visits with non-Hispanic
Whites were typically prescribed more opioids than mi-
nority counterparts across individual payment methods
(Fig. 1). Non-Hispanic Whites consistently received
more opioids in ED visits than non-Hispanic Blacks
throughout all payment methods. Non-Hispanic Whites
were prescribed more opioids than Hispanics when Me-
dicaid or self-payment was used, but not when private
insurance or another payment method was used.
Fig. 1 Opioid Prescription Rates by Demographic Factors a. a: All analyses accounts for the complex sampling design of NHAMCS. Tests are run at
95% Confidence intervals (P < 0.05). * denotes statistical significance when compared to non-Hispanic White
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Clinical factors
Assessing receipt of an opioid in the ED based on
race/ethnicity within individual pain diagnoses re-
vealed variable opioid prescribing (Fig. 2). For pa-
tients complaining of musculoskeletal pain, which
included arthritis/joint pain, pelvic pain, back pain,
and neck pain, receipt of an opioid was reported the
most in ED visits with non-Hispanic White patients
compared to both minority groups. A similar pat-
tern is seen in visits reporting fractures, other pain,
and non-pain related complaints. For ED visits asso-
ciated with abdominal pain or an injury excluding
fracture, non-Hispanic Whites were more likely to
receive opioids than non-Hispanic Blacks, but not
Hispanics.
Multivariate analyses: logistic regression
The results of the backwards stepwise regression analysis
resulted in a model of best fit that retained all loaded fac-
tors (Table 2). Race/ethnicity, age, sex, region, payment
method, pain diagnosis, and pain score all showed statisti-
cally significant adjusted odds ratios (aORs). For race/eth-
nicity, receipt of an opioid in the ED was 32% less likely to
be reported among non-Hispanic Blacks, with an aOR of
0.68 (95% CI, 0.602–0.769) compared to non-Hispanic
Whites. Additionally, Hispanics were 20.2% (aOR of 0.798,
95% CI, 0.697–0.914) less likely to have received an opioid
compared to non-Hispanic Whites.
Logistic regression analysis comparing receiving an
opioid in the ED between races/ethnicities within re-
ported pain scores demonstrated that non-Hispanic
Fig. 2 Opioid Prescription Rates by Race and Pain Diagnosis a. a: All analyses accounts for the complex sampling design of NHAMCS. Tests are
run at 95% Confidence intervals (P < 0.05). * denotes statistical significance when compared to non-Hispanic White
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Blacks were less likely to have received opioid reported
than non-Hispanic Whites, with an aOR of 0.738 (95%
CI, 0.601–0.906, p = 0.004) at a pain score of 3 and an
aOR of 0.580 (95% CI, 0.500–0.672, p < 0.001) at a pain
score of 4 (Table 3). Hispanics were also less likely than
non-Hispanic Whites to have received an opioid re-
ported at pain scores of 3 and 4 (aOR = 0.739 (95% CI,
0.578–0.945, p = 0.01) and aOR = 0.807 (95% CI, 0.685–
0.951, p = 0.011), respectively). For visits with an un-
known pain score, non-Hispanic Whites were 1.56 times
(95% CI, 1.27–1.92, p < 0.005) more likely to receive an
opioid compared to non-Hispanic Blacks. (Table 3).
Discussion
Overall, non-Hispanic Whites were more likely to re-
ceive an opioid compared to non-Hispanic Blacks and
Hispanics. In this study, we found evidence of persistent
racial disparities in the receipt of opioid agonists in the
ED over time, with non-Hispanic Whites receiving opi-
oids more frequently than non-Hispanic Blacks during
both evaluated timeframes. Additionally, we found that
racial/ethnic disparities persisted across many clinical
and nonclinical factors. Evaluating the impact of race/
ethnicity on the receipt of opioid agonists across differ-
ent adolescent age groups, results consistently showed
non-Hispanic Whites were more likely to have received
an opioid agonist while in the ED. Although overall pre-
scribing rates increased with age, non-Hispanic Whites
were more likely to have received an opioid agonist
across all age groups. This implies that disparities are
not age-dependent; however, the trend does suggest the
magnitude of disparity increases with age among
Table 2 Odds ratio of opioid prescription by race and pain score based on logistic regression analysisa
(Intercept) aORc CI 95b P-value
0.017 0.014–0.021 < 0.001
Race/Ethnicity Non-Hispanic White – – –
Hispanic 0.798 0.697–0.914 < 0.001
Non-Hispanic Black 0.680 0.602–0.769 0.001
Pain Score Pain Score 1 (No Pain) – – –
Pain Score 2 (Mild Pain) 2.107 1.728–2.568 < 0.001
Pain Score 3 (Moderate Pain) 4.019 3.388–4.769 < 0.001
Pain Score 4 (Severe Pain) 7.775 6.521–9.271 < 0.001
Pain Score 0 (No Score Reported) 2.592 2.187–3.073 < 0.001
Pain Diagnosis No Pain Diagnoses – – –
Abdominal Pain 2.226 1.973–2.510 < 0.001
Fractures 7.578 6.464–8.883 < 0.001
Injury excluding fracture 1.551 1.383–1.740 < 0.001
Musculoskeletal Pain 3.130 2.703–3.625 < 0.001
Other Pain Diagnoses 2.029 1.734–2.375 < 0.001
Region Northeast – – –
Midwest 1.536 1.271–1.856 < 0.001
South 1.904 1.612–2.250 < 0.001
West 2.318 1.877–2.863 < 0.001
Payment Method Private Insurance – – –
Medicaid, CHIP, State 0.808 0.740–0.883 < 0.001
Other Payment Method 0.889 0.777–1.018 0.088
Self-Pay 1.054 0.945–1.176 0.343
Sex Male – – –
Female 0.860 0.783–0.944 0.001
Adolescent Age 11–14 – – –
15–17 1.500 1.354–1.662 < 0.001
18–21 2.452 2.249–2.672 < 0.001
aAll analyses accounts for the complex sampling design of NHAMCS
bTests are run at 95% Confidence intervals (P < 0.05)
cadjusted odds ratio
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adolescents when comparing non-Hispanic Blacks and
non-Hispanic Whites. Further evaluation of this trend is
necessary to more fully understand the impact of age on
the likelihood of receiving an opioid while being treated
in an ED between adolescents of these two races. The
initial review of this data suggests that late adolescent
Non-Hispanic Blacks likely have seen the greatest degree
of bias when considering treatment for pain disorders
within the ED.
When evaluating the effect of sex, the results suggest
female non-Hispanic Blacks were least likely to receive
an opioid, while male non-Hispanic Whites had the
greatest likelihood. When comparing opioid prescrip-
tions across males and females of the same race/ethni-
city, there was no difference except for approximately a
20% reduction in receipt of an opioid between non-
Hispanic Black females and males. The results suggest
an amplified disparity in the treatment of pain in female
non-Hispanic Blacks compared to their male counter-
parts not seen in non-Hispanic Whites and Hispanics.
This sex-based difference deserves further research to
evaluate the intersection of sex and race in this specific
population. To date, no published research has evaluated
within race sex/gender differences in the treatment of
adolescent pain.
Within region racial/ethnic disparities consistently
showed non-Hispanic Blacks being less likely to have
opioid use than non-Hispanic Whites, except in the
West region. The largest within region difference
between races/ethnicities was seen in the Northeast,
with non-Hispanic Whites being 2.2 times more likely
than Hispanic partients and 1.7 times more likely than
non-Hispanic Black patients to receive an opioid in the
ED. These results suggest and regional aspect of racial/
ethnic disparaties that likely require specific evaluation
within individual regions. Additionally, the results of the
study suggest racial/ethnic differences in receiving an
opioid based on method of payment. Non-Hispanic
White self-pay participants were 2.2 times more likely to
have received an opioid compared to non-Hispanic
Black Medicaid participants. This highlights the import-
ance of ensuring consistent treatment regardless of pay-
ment method or race/ethnicity.
When examining the impact of clinical variables, dis-
parities were observed within same pain diagnoses and
within pain intensity scores of moderate (3 out of 4) and
severe (4 out of 4). Among adolescents with fractures,
non-Hispanic Whites were 1.34 times more likely to
have received an opioid than non-Hispanic Blacks and
1.24 times more likely than Hispanics. These disparities
were even more pronounced in musculoskeletal pain
and abdominal pain. Although severity of fractures and
pain related to individual diagnoses can vary dependent
on the clinical situation, the substantial reduction in the
receipt of an opioid among non-White participants
raises significant concern of discrimination in the treat-
ment of pain, regardless of individual clinical factors.
The results of this study provide a more thorough
evaluation of the role of race/ethnicity on the likelihood
of receiving an opioid to treat pain in adolescent patients
within EDs. Previous research has been limited on find-
ing when clinical and demographic factors are accounted
for, race/ethinicity disparities persist [7–9]. This evi-
dence further supports the presence of racial-bias of pre-
scribers when treating pain conditions within the ED
and the need to develop more robust treatment guide-
lines and prescribing policies related to the use of opi-
oids in the treatment of pain in adolescents. The current
lack of such guideline or universal prescribing policies
may too easily allow for the introduction of bias into
prescribing decisions.
To our knowledge, this is the first study to conduct an
analysis of the role of race/ethnicity on the receipt of
opioid agonists among adolescents while accounting for
potential contributing factors. Previous studies evaluat-
ing trends in opioid use among pediatric patients have
reported differences in opioid use based on race/ethni-
city [3, 7, 8]; however, those studies did little to evaluate
the impact of other nonclinical demographic factors and
clinical factors. Additionally, previous research has often
combined the receipt of opioids with non-narcotic pain
medications, such as, acetaminophen and non-steroidal
inflammatory drugs [9, 13]. Although the use of
Table 3 Odds ratio of opioid prescription by race and pain
score based on logistic regression analysisa
Race/ethnicies Pain Score aORc CI 95b P-value
Intercept 0.050 0.041–0.061 < 0.001
Non-Hispanic White 1 – – –
Non-Hispanic Black 1 0.803 0.550–1.171 0.245
Hispanic 1 0.963 0.620–1.496 0.866
Intercept 2 0.138 0.116–0.166 < 0.001
Non-Hispanic White 2 – –
Non-Hispanic Black 2 0.885 0.625–1.252 0.489
Hispanic 2 0.734 0.515–1.046 0.087
Intercept 3 0.287 0.256–0.323 < 0.001
Non-Hispanic White 3 – –
Non-Hispanic Black 3 0.738 0.601–0.906 0.004
Hispanic 3 0.739 0.578–0.945 0.016
Intercept 4 0.601 0.550–0.656 < 0.001
Non-Hispanic White 4 – –
Non-Hispanic Black 4 0.580 0.500–0.672 < 0.001
Hispanic 4 0.807 0.685–0.951 0.011
aAll analyses accounts for the complex sampling design of NHAMCS
bTests are run at 95% Confidence intervals (P < 0.05)
cadjusted odds ratio
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nonopioid pain medications can be considered as an al-
ternative treatment in some clinical situations, the use of
such agents should not differ based on patient race or
ethnicity.
Limitations
Limitations of this study include its retrospective nature
and the general limitations of using a cross-sectional
data set. Owing to this limitation, we can only report the
findings of the analysis and are not able to draw conclu-
sions about causality. Additionally, other factors may
need to be further explored to understand their role in
opioid use patterns, including the impact of prescriber
specific factors, health system factors, and changes to
standards of practice. For example, patient-provider con-
cordance (i.e. patients seeing providers who are of the
same race/ethnicity) has been demonstrated to have an
affect on a pediatric patient’s chances of receiving an
opioid and was not evaluated in the current study [32].
In addition, a number of comorbidities may affect the
choice of drug for pain management and are not
accounted for in this presented study. Lastly, it is im-
portant to note that race and ethnicity reporting col-
lected was based on health record recording, which are
often practitioner defined and not reported directly by
patients. Although this may have resulted in incorrect
race and ethnicity assignment, the focus of this paper is
the impact race and ethnicity has on practitioner deci-
sions regarding the use of opioids in the ED. This sug-
gests practitioners’ perceptions of patient race and
ethnicity is as important as a patient’s self identification
of race and ethnicity in answering the objectives of the
study.
Conclusion
The finding of this study suggests racial/ethnic dispar-
ities in the receipt of opioids in EDs in the U.S. persisted
from 2006 to 2016. The likelihood to recieve an opioid
was greatest among non-Hispanic Whites and lowest in
non-Hispanic Blacks. When accounting for various pa-
tient demographic factors (region of care, payment
method, sex, and age) and clinical factors (pain diagnosis
and pain score), the racial and ethnic disparities
remained present. Previous research has exposed the ra-
cial and ethnic differences in opioid use, but, to date,
this study is the first to evaluate the impact of multiple
patient specific factors to determine if non-race/ethnicity
driven factors could explain the inconsistencies in care.
The findings of this study further support the existence
of racial and ethnic biases in opioid prescribing trends.
Of particular concern is the significant difference re-
ported in opioid use in female non-Hispanic Blacks as
compared to both their male counterparts and non-
Hispanic White and Hispanic females. In addition, the
increased degree of racial/ethnic inconsistencies re-
ported by certain regions raises concern over the pre-
scribing patterns reported in those areas. Lastly, the
existence of significant variability in the use of opioids
across different races/ethnicities while holding constant
clinical factors suggest more efforts are needed to create
evidence-based treatment recommendations for the use
of opioids in adolescents to help improve the
consistency in care.
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